"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

In a groundbreaking study, scientists at the U.S. Department of Agriculture, Agricultural Research Service (ARS) redefined ...

In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across ...

In an effort to extend financing support for patients seeking CAR-T cell therapy, Immuneel Therapeutics has partnered with ...

Gujarat is leading India's solar cell manufacturing with significant investments and capacity expansions, positioning itself ...

Their shared dedication reflects a broader mission to bring meaningful change to women’s health, offering hope and tangible ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S ...

More than five decades after Indian naval strikes crippled Karachi during the 1971 war, undersea power is once again at the ...

After 15 years reporting on the solar industry, and many more years removed from organized education where math and science ...

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today ...